ALNY
Alnylam Pharmaceuticals, Inc.$159.51-5.46 (-3.31%)Prev Close$165.04·MCap$21.41B·P/E39.09·Vol1.50M·Yield—
▲
Buys (12M)
2
$543.1K
▼
Sells (12M)
26
$31.28M
◆
Net Activity
Net Seller
$30.73M
●
Active Insiders
10
last 12 mo
Over the past 12 months, insider activity at Alnylam Pharmaceuticals, Inc. (ALNY) has been dominated by selling, with 2 insider purchases totaling $543.1K and 26 insider sales totaling $31.28M. The most recent insider transaction was by SCHULMAN AMY W (director), who purchased $299.5K worth of shares on Nov 12, 2026. Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $21.41B.
ALNY Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHULMAN AMY W | director | Buy | 1,910 | $156.82 | $299.5K | 25,959 |
| Nov 12, 2026 | Sigal Charles Elliott | director | Buy | 1,600 | $152.25 | $243.6K | 3,600+80% |
| Oct 6, 2026 | SUPRAN BRYAN | officer: EVP, CLO and Secretary | Sell | 1,758 | $226.88 | $398.9K | 12,807 |
| Jun 3, 2026 | PYOTT DAVID E I | director | Sell | 3,830 | $299.18 | $1.15M | 4,491-46% |
| Apr 7, 2026 | McLaughlin Melissa | officer: Chief Human Resources Officer | Sell | 3,910 | $325.92 | $1.27M | 13,088 |
| Mar 6, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,291 | $323.54 | $417.7K | 21,831 |
| Mar 6, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,713 | $323.53 | $1.52M | 23,300 |
| Mar 6, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 2,933 | $323.08 | $947.6K | 98,493 |
| Mar 6, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797.4K | 64,159 |
| Mar 6, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $746.0K | 36,500 |
| Mar 2, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,627 | $331.34 | $1.53M | 26,629 |
| Feb 17, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 4,000 | $321.24 | $1.28M | 23,305 |
| Feb 17, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 2,242 | $310.08 | $695.2K | 24,848 |
| Feb 17, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 13,916 | $310.08 | $4.32M | 85,662 |
| Feb 17, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 59,802 |
| Feb 17, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 31,769 |
| Feb 12, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,041 | $331.96 | $677.5K | 0 |
| Feb 12, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 0 |
| Feb 12, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 0 |
| Jan 14, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,450 | $362.63 | $525.8K | 25,025 |
| Jan 14, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,429 | $362.45 | $517.9K | 31,199 |
| Jan 11, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,290 | $370.33 | $848.1K | 0 |
| Jan 11, 2026 | Garg Pushkal | EVP Chief R&D | Sell | 1,510 | $362.87 | $547.9K | 0 |
| Jan 11, 2026 | Greenstreet Yvonne | Chief Executive Officer | Sell | 9,577 | $362.86 | $3.48M | 0 |
| Jan 11, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,780 | $362.87 | $1.01M | 0 |
| Jan 11, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 21 | $371.02 | $7.8K | 0 |
| Nov 26, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 1,121 | $445.12 | $499.0K | 0 |
| Nov 17, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 12,128 | $452.18 | $5.48M | 0 |
| Nov 12, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 25,650 | $452.75 | $11.61M | 0 |
| Oct 1, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,441 | $452.05 | $1.10M | 0 |
| Oct 1, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 5,956 | $451.76 | $2.69M | 0 |
| Oct 1, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 8,924 | $452.05 | $4.03M | 0 |
| Oct 1, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 3,821 | $452.05 | $1.73M | 0 |
| Oct 1, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,405 | $452.05 | $635.1K | 0 |
| Sep 9, 2025 | Reitan Colleen F | Director | Sell | 18,000 | $467.60 | $8.42M | 0 |
| Aug 29, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 3,474 | $448.37 | $1.56M | 0 |
| Aug 18, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $450.00 | $5.06M | 0 |
| Aug 15, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 2,851 | $455.89 | $1.30M | 0 |
| Aug 15, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 6,979 | $453.27 | $3.16M | 0 |
| Aug 15, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,274 | $453.27 | $1.03M | 0 |
| Aug 14, 2025 | Ausiello Dennis A | Director | Sell | 31,448 | $436.58 | $13.73M | 0 |
| May 30, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 50,937 | $305.00 | $15.54M | 0 |
| May 15, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $277.71 | $3.12M | 0 |
| Mar 24, 2025 | PYOTT DAVID E I | Director | Sell | 7,440 | $299.00 | $2.22M | 0 |
| Mar 21, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 9,766 | $293.36 | $2.86M | 0 |
| Mar 3, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,755 | $242.94 | $669.3K | 0 |
| Mar 3, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 2,556 | $242.92 | $620.9K | 0 |
| Mar 3, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 3,877 | $243.79 | $945.2K | 0 |
| Mar 3, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 1,263 | $243.78 | $307.9K | 0 |
| Mar 3, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 471 | $243.78 | $114.8K | 0 |
Showing 1–50 of 135
1 / 3
ALNY Insider Buying Activity
The following table shows recent insider purchases of Alnylam Pharmaceuticals, Inc. (ALNY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHULMAN AMY W | director | Buy | 1,910 | $156.82 | $299.5K | 25,959 |
| Nov 12, 2026 | Sigal Charles Elliott | director | Buy | 1,600 | $152.25 | $243.6K | 3,600+80% |
ALNY Insider Selling Activity
The following table shows recent insider sales of Alnylam Pharmaceuticals, Inc. (ALNY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | SUPRAN BRYAN | officer: EVP, CLO and Secretary | Sell | 1,758 | $226.88 | $398.9K | 12,807 |
| Jun 3, 2026 | PYOTT DAVID E I | director | Sell | 3,830 | $299.18 | $1.15M | 4,491-46% |
| Apr 7, 2026 | McLaughlin Melissa | officer: Chief Human Resources Officer | Sell | 3,910 | $325.92 | $1.27M | 13,088 |
| Mar 6, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,291 | $323.54 | $417.7K | 21,831 |
| Mar 6, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,713 | $323.53 | $1.52M | 23,300 |
| Mar 6, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 2,933 | $323.08 | $947.6K | 98,493 |
| Mar 6, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797.4K | 64,159 |
| Mar 6, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $746.0K | 36,500 |
| Mar 2, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,627 | $331.34 | $1.53M | 26,629 |
| Feb 17, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 4,000 | $321.24 | $1.28M | 23,305 |
| Feb 17, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 2,242 | $310.08 | $695.2K | 24,848 |
| Feb 17, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 13,916 | $310.08 | $4.32M | 85,662 |
| Feb 17, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 59,802 |
| Feb 17, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 31,769 |
| Feb 12, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,041 | $331.96 | $677.5K | 0 |
| Feb 12, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 0 |
| Feb 12, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 0 |
| Jan 14, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,450 | $362.63 | $525.8K | 25,025 |
| Jan 14, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,429 | $362.45 | $517.9K | 31,199 |
| Jan 11, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,290 | $370.33 | $848.1K | 0 |
| Jan 11, 2026 | Garg Pushkal | EVP Chief R&D | Sell | 1,510 | $362.87 | $547.9K | 0 |
| Jan 11, 2026 | Greenstreet Yvonne | Chief Executive Officer | Sell | 9,577 | $362.86 | $3.48M | 0 |
| Jan 11, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,780 | $362.87 | $1.01M | 0 |
| Jan 11, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 21 | $371.02 | $7.8K | 0 |
| Nov 26, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 1,121 | $445.12 | $499.0K | 0 |
| Nov 17, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 12,128 | $452.18 | $5.48M | 0 |
| Nov 12, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 25,650 | $452.75 | $11.61M | 0 |
| Oct 1, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,441 | $452.05 | $1.10M | 0 |
| Oct 1, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 5,956 | $451.76 | $2.69M | 0 |
| Oct 1, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 8,924 | $452.05 | $4.03M | 0 |
| Oct 1, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 3,821 | $452.05 | $1.73M | 0 |
| Oct 1, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,405 | $452.05 | $635.1K | 0 |
| Sep 9, 2025 | Reitan Colleen F | Director | Sell | 18,000 | $467.60 | $8.42M | 0 |
| Aug 29, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 3,474 | $448.37 | $1.56M | 0 |
| Aug 18, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $450.00 | $5.06M | 0 |
| Aug 15, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 2,851 | $455.89 | $1.30M | 0 |
| Aug 15, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 6,979 | $453.27 | $3.16M | 0 |
| Aug 15, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,274 | $453.27 | $1.03M | 0 |
| Aug 14, 2025 | Ausiello Dennis A | Director | Sell | 31,448 | $436.58 | $13.73M | 0 |
| May 30, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 50,937 | $305.00 | $15.54M | 0 |
| May 15, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $277.71 | $3.12M | 0 |
| Mar 24, 2025 | PYOTT DAVID E I | Director | Sell | 7,440 | $299.00 | $2.22M | 0 |
| Mar 21, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 9,766 | $293.36 | $2.86M | 0 |
| Mar 3, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,755 | $242.94 | $669.3K | 0 |
| Mar 3, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 2,556 | $242.92 | $620.9K | 0 |
| Mar 3, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 3,877 | $243.79 | $945.2K | 0 |
| Mar 3, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 1,263 | $243.78 | $307.9K | 0 |
| Mar 3, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 471 | $243.78 | $114.8K | 0 |
ALNY Insiders
Similar Stocks to ALNY
VRTX
Vertex Pharmaceuticals Incorporated
$536.14-0.42%
$138.69B
REGN
Regeneron Pharmaceuticals, Inc.
$948.88-0.62%
$99.23B
MRNA
Moderna, Inc.
$214.97-3.55%
$93.61B
RVMD
Revolution Medicines, Inc.
$166.45-3.42%
$39.08B
INSM
Insmed Incorporated
$122.96+1.38%
$26.58B
UTHR
United Therapeutics Corporation
$585.50-0.96%
$25.18B
INCY
Incyte Corporation
$120.12-0.66%
$24.66B
NBIX
Neurocrine Biosciences, Inc.
$165.17-1.30%
$16.94B